Table 1.
Characteristics of patients with and without apathy at baseline
| Total sample | AD | DLB | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Nonapathy (n = 124) |
Apathy (n = 72) |
p Value* | Nonapathy (n = 85) |
Apathy (n = 35) |
p Value* | Nonapathy (n = 39) |
Apathy (n = 37) |
p Value* | |
| AD/DLB (%) | 68.5/31.5 | 48.6/51.4 | .006 | ||||||
| Sex, male/female | 39/85 | 33/39 | .044 | 64/21 | 22/13 | .169 | 21/18 | 17/20 | .491 |
| Age, years (SD) | 76.2 (7.2) | 75.8 (8.6) | .702 | 75.7 (7.7) | 75.7 (7.8) | .865 | 77.3 (5.9) | 75.9 (8.2) | .382 |
| Education, years (SD) | 9.8 (3.1) | 9.3 (2.6) | .311 | 9.7 (3.1) | 9.2 (2.3) | .497 | 9.9 (3.0) | 9.4 (2.9) | .400 |
| CDR global (IQR) | 0.8 (0.5) | 1.0 (0.0) | <.001 | 0.7 (0.5) | 1.0 (0.0) | <.001 | 0.9 (0.5) | 1.1 (0.4) | .072 |
| Depression, NPI (SD) | 1.4 (1.9) | 3.2 (3.1) | <.001 | 1.4 (1.9) | 3.2 (3.1) | .001 | 1.3 (1.8) | 3.2 (3.0) | .003 |
| UPDRS (SD) | 6.4 (10.6) | 7.6 (10.4) | .175 | 1.5 (2.6) | 2.5 (4.0) | .296 | 15.9 (13.6) | 12.4 (12.2) | .245 |
| CIRS (SD) | 5.5 (2.4) | 6.3 (2.7) | .034 | 5.1 (2.1) | 5.7 (2.5) | .244 | 6.5 (2.9) | 6.8 (2.8) | .641 |
| Duration of dementia symptoms before baseline, months (SD) | 34.8 (21.9) | 40.8 (24.7) | .104 | 32.4 (21.3) | 36.6 (22.5) | .298 | 40.0 (22.4) | 44.9 (26.4) | .396 |
| Dementia medication at baseline, yes (%) | 52.7 | 35.8 | .029 | 51.9 | 41.2 | .296 | 54.8 | 30.3 | .047 |
| Dementia medication at follow-up 1, yes (%) | 74.5 | 79.6 | .477 | 71.6 | 80.0 | .384 | 81.5 | 79.2 | .835 |
Abbreviations: AD Alzheimer’s disease, DLB Dementia with Lewy bodies, CDR Clinical Dementia Rating, CIRS Cumulative Illness Rating Scale, UPDRS Unified Parkinson’s Disease Rating Scale
* Differences were analyzed using the Mann-Whitney U test and Pearson’s chi-square test